

## Qiagen

Qiagen GmbH  
40724 Hilden, Germany  
Germantown, MD 20874  
Phone: +492103290

[www.qiagen.com](http://www.qiagen.com)

No. of employees: 4,700

Category: Diagnostics

QIAGEN N.V., incorporated on April 29, 1996, is a holding company. The Company, through its subsidiaries, provides Sample & Assay Technologies. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions. It also provides Ingenuity Variant Analysis, a cloud-based platform that interprets data from next-generation sequencing (NGS) analysis; QIAGEN Clinical Insight, an evidence-based decision support solution; CLC Genomics Workbench for the analysis and visualization of data from various NGS platforms; and GeneGlobe, a Web-based portal that enables researchers to search and select gene-and pathway-specific solutions from pre-designed and custom PCR assay kits, NGS assay panels, and other products.

Its automation platforms include QIASymphony, a modular system; GeneReader NGS System, a sample to insight NGS solution for laboratories to deliver actionable results; QIAcube robotic workstations, which provides versatile solutions for automated sample processing; QIAxcel for nucleic acid separation; QIAgility, a benchtop instrument for PCR setup; and ESEQuant instruments that enable optical measurement for point of need molecular testing in physician practices, emergency rooms, remote areas, and other applications. It serves molecular diagnostics, applied testing, pharma, and academia customers.

QIAGEN N.V. has a collaboration with Bristol-Myers Squibb to develop gene expression profiles for immuno-oncology therapies. The FDA has approved the theascreen EGFR RGQ PCR Kit to guide the use of the new targeted therapy Gilotrif (afatinib) from Boehringer Ingelheim, which received FDA approval for use in metastatic non-small cell lung cancer (NSCLC) patients. The theascreen KRAS RGQ PCR Kit is paired for use with Erbitux (cetuximab) from Eli Lilly and Company and Bristol-Myers Squibb for metastatic colorectal cancer patients.

Qiagen recently announced a partnership with Freenome to provide Artificial Intelligence solutions in support of their GeneReader NGS System. The company strategy generally emphasizes NGS and this is especially so in the immuno-oncology space. The company is very active in companion diagnostics (generally Immuno-oncology related) with an expanding product line built around the GeneReader system that addresses both liquid biopsy and tissue samples with an emphasis on clinically actionable results.